LEONTEQ SECURITIES AG (GUERNSEY BRANCH) | Market Closed - Swiss Exchange 16:20:00 24/06/2024 BST | ||
| 103.8 GBX | +0.08% |
|
| 3 months | +0.66% | ||
| 6 months | +0.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 103.8 | +0.08% |
| 20/06/24 | 103.7 | +0.20% |
| 19/06/24 | 103.5 | +0.15% |
Delayed Quote Swiss Exchange
Last update June 24, 2024 at 04:20 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | LEONTEQ |
| XKQLTQ | |
| ISIN | CH1277653320 |
| Date issued | 03/07/2023 |
| Strike | 7,630 p |
| Maturity | 03/01/2025 (188 Days) |
| Parity | 0.08 : 1 |
| Emission price | 100 p |
| Emission volume | N/A |
| Settlement | both |
| Currency | GBX |
Technical Indicators
| Highest since issue | 104.2 p |
|---|---|
| Lowest since issue | 98.84 p |
| Spread | 8.3 p |
| Spread % | 0.79% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.69%
- Stock Market
- Certificates
- XKQLTQ Certificat
